Status:

UNKNOWN

Homocysteine Lowering and Atherosclerosis Reduction Trial (HART)

Lead Sponsor:

Hamilton Health Sciences Corporation

Collaborating Sponsors:

Canadian Institutes of Health Research (CIHR)

Population Health Research Institute

Conditions:

Atherosclerosis

Cardiovascular Disease

Eligibility:

All Genders

55+ years

Phase:

PHASE4

Brief Summary

Study Objective: 1\. To evaluate whether combined therapy with folic acid 2.5 mg/day, vitamin B6 50 mg/day and vitamin B12 1000 micrograms/day vs placebo reduces the rate of atherosclerosis progressi...

Detailed Description

The HART study is designed as a substudy of the Heart Outcomes Prevention Evaluation-2 (HOPE-2)trial which evaluates the effect of combined therapy ? folic acid and vitamin B6 and B12 on clinical even...

Eligibility Criteria

Inclusion

  • Women and Men aged ≥ 55 years at high risk for CV events with: (a) Documented (CAD): i) History of prior MI; ii) stable or unstable angina with documented multivessel CAD or strongly positive stress test; iii) Multivessel CAD and PTCA ≥ 6 months prior to randomization; iv) multivessel CABG ≥ 4 years prior to randomization; v) Multivessel CAD on angiography; (b) Documented peripheral vascular disease (PVD): i) Previous limp bypass surgery and/or previous peripheral percutaneous transluminal angioplasty and/or previous limp or foot amputation due to PVD.ii) History of intermittent claudication with ankle/arm blood pressure ratio of ≤ 0.80 or with significant arterial stenosis on angiography; (c) Documented cerebrovascular disease: i) History of previous ischemic stroke; and (d) Diabetes mellitus with ≥ 1 additional major CV risk factor(s). (2) Provision of informed consent.(3) Adequate baseline carotid US examination.

Exclusion

  • Current use of folic acid supplements \> 200 mg/day. 2. Known previous adverse reactions to folic acid, Vitamin B6 or B12. 3. Planned cardiac, peripheral or cerebrovascular.
  • \-

Key Trial Info

Start Date :

January 1 2000

Trial Type :

INTERVENTIONAL

End Date :

October 1 2005

Estimated Enrollment :

900 Patients enrolled

Trial Details

Trial ID

NCT00217178

Start Date

January 1 2000

End Date

October 1 2005

Last Update

September 22 2005

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hamilton Health Sciences Corp.

Hamilton, Ontario, Canada, L8L 2X2

Homocysteine Lowering and Atherosclerosis Reduction Trial (HART) | DecenTrialz